DDInter1323 DDInter740
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Octreotide {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Octreotide {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Metoprolol {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Metoprolol {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Carvedilol {u} (Compound) binds {v} (Gene) GJA1
GJA1 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pindolol
Pindolol {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pindolol
Pindolol {u} (Compound) downregulates {v} (Gene) SUPV3L1
SUPV3L1 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Octreotide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Octreotide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol (Compound) binds GJA1 (Gene) and GJA1 (Gene) is downregulated by Flecainide (Compound)
Octreotide may lead to a major life threatening interaction when taken with Lonafarnib and Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Flecainide (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) downregulates SUPV3L1 (Gene) and SUPV3L1 (Gene) is downregulated by Flecainide (Compound)